Cell Therapy Deals Are Up 800% in 2026 — Here's the Data

Eight cell therapy deals closed between March 22 and September 22, 2026 — up from zero in the prior six-month window. That's an 800% increase, and it isn't a statistical artifact from a low base. It reflects a decisive capital reallocation by Big Pharma into next-generation cell therapy platforms, driven by the convergence of allogeneic manufacturing breakthroughs, FDA regulatory clarity on in vivo cell engineering, and a genuine pipeline panic among top-10 pharma companies facing LOE cliffs between 2028 and 2031.

The Data — Cell Therapy Deal Activity, Period over Period

The zero-to-eight jump deserves context. Cell therapy licensing activity had been muted through late 2025 and early 2026 for structural reasons: several high-profile CAR-T programs hit clinical holds, manufacturing scale-up failures spooked acquirers, and the FDA's updated RMAT guidance created a temporary pause while sponsors recalibrated regulatory strategies. The dam broke in Q2 2026. Once it did, the velocity and scale of cell therapy deal trends 2026 outpaced anything we tracked in the antibody or ADC categories over the same window.

What's Driving the Trend

Manufacturing maturity is the unlock. The first generation of autologous CAR-T deals (2017–2023) was constrained by vein-to-vein logistics, COGs north of $300K per dose, and turnaround times that killed patients before their therapy was ready. The deals closing now — Poseida/Roche, Kelonia/Lilly — center on allogeneic or in vivo delivery platforms that credibly address these bottlenecks. Poseida's non-viral piggyBac system eliminates viral vector dependency. Kelonia's lentiviral delivery platform targets in vivo CAR-T generation, sidestepping ex vivo manufacturing entirely. Pharma BD teams are no longer buying science projects; they're buying scalable production architectures.

Pipeline gap anxiety is accelerating timelines. Roche, Lilly, and Merck KGaA each face significant revenue exposure from biosimilar erosion and LOE events between 2028 and 2032. Cell therapy — particularly in solid tumors, autoimmune indications, and fibrosis — represents a durable franchise opportunity that small molecules and biologics haven't cracked. The $7B total deal value on Kelonia/Lilly and the $11.3B Bio-Techne/Merck KGaA transaction signal that these aren't toe-in-the-water option deals. These are full-platform bets. The cell therapy licensing 2026 wave is strategic, not opportunistic.

Regulatory momentum matters. The FDA's 2026 draft guidance on in vivo gene-modified cell therapies, combined with accelerated RMAT designations for allogeneic programs in large B-cell lymphoma and lupus nephritis, gave pharma legal and regulatory teams enough confidence to greenlight transactions that had been sitting in diligence for 12+ months. Regulatory risk was the last excuse for inaction — and the agency removed it.

Notable Deals

Bio-Techne / Merck KGaA ($11.3B TDV) is the headline transaction — and it's not a typical licensing deal. The two entries in June 2026 suggest an evolving term sheet that culminated in a full acquisition or expanded platform agreement. At $11.3B, Merck KGaA is paying for Bio-Techne's enabling technology stack (cell analysis, proteins, reagents) that underpins GMP-grade cell therapy manufacturing. This is an infrastructure play, not a pipeline play. It signals that pharma sees cell therapy as an industrial capability to own, not just a program to license.

Kelonia / Lilly ($7B TDV) validates in vivo cell engineering as a commercially viable modality. Lilly's bet on Kelonia's lentiviral platform for in vivo CAR-T generation is the most forward-looking deal in this cohort. The $7B headline reflects milestone-heavy structure, but the strategic intent is clear: Lilly wants to eliminate the manufacturing bottleneck entirely by engineering T cells inside the patient. If the Phase 2 data holds, this deal will look cheap. Compare this to Deal Benchmarks for cell therapy transactions — median TDV for platform deals has climbed 3x since 2024.

Poseida / Roche ($1.5B TDV) is the most disciplined deal in the set. Roche is paying a measured price for Poseida's allogeneic CAR-T programs, likely structured with significant clinical milestones. At $1.5B, this sits below the cohort median — which either reflects Roche's negotiating leverage or earlier-stage programs. Either way, it's a strong comp for Series C–D biotechs benchmarking their own platform value.

MaxCyte / Genentech — the absence of disclosed financial terms here is notable. MaxCyte's electroporation platform is an enabling technology for non-viral cell engineering. This deal likely involves a technology access agreement rather than a traditional licensing structure. Watch for MaxCyte's next 10-Q to reveal milestone and royalty details.

What This Means for BD Teams Right Now

If you're selling a cell therapy platform, this is the best market in five years. Eight deals in six months with three transactions exceeding $7B TDV means pharma is in acquisition mode, not browsing mode. Allogeneic platforms, in vivo delivery systems, and manufacturing enablers are commanding premium valuations. If you have Phase 1 data and a differentiated manufacturing approach, your leverage is at a cyclical peak. Do not accept option-heavy deal structures with deferred value when competitors are paying up front at scale.

If you're buying, move now — but structure defensively. The window of platform availability is closing. Kelonia, Poseida, and Bio-Techne are off the board. The remaining independent cell therapy platforms with clinical-stage assets are a shrinking pool. That said, the premium environment means you should insist on milestone-gated structures tied to manufacturing scalability proof points, not just clinical endpoints. Use Solidus to stress-test your term sheet against the five deals above — particularly on royalty rates and co-commercialization rights, which are the key negotiation battlegrounds in cell therapy licensing 2026.

Deal structures are shifting. The Bio-Techne/Merck KGaA transaction suggests full acquisitions are back on the table for enabling technology companies — not just pipeline-stage biotechs. BD teams should prepare for hybrid structures: upfront equity stakes with bolt-on licensing agreements, technology access platforms with option-to-acquire triggers, and co-development arrangements that share manufacturing risk. Pure option deals with low upfront commitments are losing seller acceptance in this market.

Benchmark your deal against current market rates. The cell therapy deal landscape has repriced dramatically in the first half of 2026. Whether you're structuring a term sheet, evaluating an inbound offer, or advising a board on strategic alternatives, use the Ambrosia calculator to model your transaction against verified comps from this cycle.